The House Energy and Commerce Subcommittee on Oversight and Investigations today held the second part of a hearing on the rising cost of insulin, which featured witnesses from the nation’s three insulin manufacturers as well as three pharmacy benefit managers.
 
“It appears that there is limited competition and little incentive to keep prices at a level that patients can afford,” Committee Chairman Frank Pallone, D-N.J., said in opening remarks. “And perhaps there are incentives in place to keep raising prices. As a result, we are left with a drug that has been available for nearly 100 years, and yet the price tripled and then doubled in just the last couple decades. Clearly, something is not right here.”
 
During the first part of the hearing last week, diabetes care witnesses described the impact of rising insulin prices on patients.

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…